Defence Therapeutics Inc.
Defence Therapeutics Inc.
Your view on DTC.CN
Overview
What the company does, where it operates, and who runs it.
About Defence Therapeutics Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Sebastien Plouffe
- Headquarters
- CA
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Sebastien Plouffe
- Headquarters
- CA
Defence Therapeutics Inc., a biotechnology company, engages in the research and development of biological/biosimilar therapeutic drugs for cancer and infectious diseases. Its proprietary platform is the ACCUMTM technology, which enables precision delivery of vaccine antigens or ADCs in their intact form to target cells.
The company focuses on developing dendritic cell cancer vaccines; protein-based vaccine formulation against COVID and infectious diseases; and antibody drug conjugates (ADC) products targeting various cancers. The company was formerly known as Accum Therapeutics Inc. and changed its name to Defence Therapeutics Inc. in March 2020.
Defence Therapeutics Inc. was incorporated in 2017 and is headquartered in Vancouver, Canada.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Defence Therapeutics Inc., and the rating behind it. DTC.CN last traded at C$0.74; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Defence Therapeutics Inc.. Starting points for Defence Therapeutics Inc.: EPS -C$0.11, beta 1.34 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Defence Therapeutics Inc.. Defence Therapeutics Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Defence Therapeutics Inc.. Trailing twelve-month EPS for Defence Therapeutics Inc. stands at -C$0.11. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Defence Therapeutics Inc.. Defence Therapeutics Inc. has reported as a listed company since 2021. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Defence Therapeutics Inc. valued side by side against its closest peers. Defence Therapeutics Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Defence Therapeutics Inc., and how their positions are changing. At a C$40.5M market value, institutional positions materially move Defence Therapeutics Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Defence Therapeutics Inc. executives and directors. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Defence Therapeutics Inc.. Defence Therapeutics Inc. is a C$40.5M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Defence Therapeutics Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Defence Therapeutics Inc.. Coverage tracks Defence Therapeutics Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.